{"changes":[],"country":"FR","description":"Apmonia Therapeutics develops peptide-based immunotherapies that disrupt the tumor micro-environment and stimulate immune response in solid tumors. It serves oncologists and patients with cancers where existing checkpoint inhibitors are ineffective. The TAX2 peptide-driven approach targets thrombospondin pathways that small-molecule and antibody oncology programs have largely left untouched.","domain":"apmoniatherapeutics.com","employees":null,"founded":2017,"fundingTotalQuarantined":false,"githubOrg":null,"githubStars":null,"industry":"bio","investors":[],"lat":48.693722,"lng":6.18341,"location":"Nancy, France","name":"APMONIA THERAPEUTICS","rounds":[{"amountQuarantined":false,"amountUsd":2624400,"currency":"EUR","date":"2024-07-15","investors":[],"leadInvestor":null,"source":{"fact":"round","publisher":"eu-grant","retrievedAt":"2026-05-08","status":"attributed","url":null},"status":"attributed","type":"grant","url":null}],"slug":"apmoniatherapeutics-com","sources":[{"fact":"round","publisher":"eu-grant","retrievedAt":"2026-05-08","status":"attributed","url":null},{"fact":"existence","publisher":"apmoniatherapeutics.com","retrievedAt":"2026-05-08","status":"self-reported","url":"https://apmoniatherapeutics.com"},{"fact":"description","publisher":"apmoniatherapeutics.com","retrievedAt":"2026-05-08","status":"self-reported","url":"https://apmoniatherapeutics.com"}],"stage":null,"techStack":[],"totalRaisedUsd":2624400,"updatedAt":"2026-05-08"}